ArticleVeterinary medicine and science2026
Omeprazole as a Novel Treatment Option for Giardiasis in Cats.
Article in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGiardiasis is a common protozoal infection in cats, often treated with nitroimidazole derivatives such as metronidazole and secnidazole. However, there are concerns about resistance to nitroimidazoles and their adverse effects. Recent in vitro studies suggest that omeprazole, a proton pump inhibitor, exhibits anti-giardial effects by inhibiting giardial triosephosphate isomerase. No clinical studies have evaluated its efficacy in naturally infected cats.
objectivesThis study aimed to assess and compare the anti-giardial efficacy of omeprazole, metronidazole, and secnidazole in cats naturally infected with Giardia duodenalis, based on faecal cyst shedding and clinical parameters.
methodsForty-eight naturally infected cats were randomly assigned to four groups: omeprazole (1 mg/kg/day for 7 days), metronidazole (25 mg/kg twice daily for 7 days), secnidazole (30 mg/kg single dose), and placebo. Faecal cyst shedding was evaluated using the zinc sulphate flotation technique on days 0, 7 and 14. Faecal consistency was scored daily, and haematological parameters were assessed on days 0, 7 and 14.
resultsBy day 7, faecal cyst positivity was 50% in both the omeprazole and metronidazole groups, 58.3% in the secnidazole group, and 83.3% in the placebo group. The reduction observed in the omeprazole and metronidazole groups was statistically significant compared with the placebo (p < 0.05). By day 14, cyst positivity further decreased to 33.3% (omeprazole), 41.7% (metronidazole), and 50% (secnidazole), with omeprazole showing the lowest positivity rate among the treatments. Faecal scores improved significantly earlier in the omeprazole and metronidazole groups compared with secnidazole and placebo (p < 0.05).
conclusionsOmeprazole demonstrated promising anti-giardial efficacy, with reductions in cyst shedding and improvements in faecal consistency comparable to metronidazole. These findings suggest that omeprazole may serve as a potential alternative treatment option for feline giardiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.